Skip to content
TrialScanner

NCT03917043

APG-2449 in Patients With Advanced Solid Tumors

Phase 1RecruitingAAPGLead

Registry record

Lead sponsor
Ascentage Pharma Group Inc.
Conditions
Advanced Solid Cancer; Non Small Cell Lung Cancer; Esophageal Cancer; Ovarian Cancer; Malignant Pleural Mesothelioma
Primary completion
Dec 2027Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT03917043 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03917043: APG-2449 in Patients With... | TrialScanner